Pulmatrix, Inc. – NASDAQ:PULM
Pulmatrix stock price today
Pulmatrix stock price monthly change
Pulmatrix stock price quarterly change
Pulmatrix stock price yearly change
Pulmatrix key metrics
Market Cap | 21.03M |
Enterprise value | N/A |
P/E | -0.57 |
EV/Sales | -5.70 |
EV/EBITDA | 3.48 |
Price/Sales | 2.24 |
Price/Book | 0.31 |
PEG ratio | -0.02 |
EPS | -2.41 |
Revenue | 11.68M |
EBITDA | -8.48M |
Income | -8.84M |
Revenue Q/Q | 292.59% |
Revenue Y/Y | 82.27% |
Profit margin | -219.42% |
Oper. margin | -218.37% |
Gross margin | 30.46% |
EBIT margin | -218.37% |
EBITDA margin | -72.63% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePulmatrix stock price history
Pulmatrix stock forecast
Pulmatrix financial statements
| Jun 2023 | 1.84M | -3.81M | -206.94% |
|---|---|---|---|
| Sep 2023 | 1.75M | -3.77M | -215.29% |
| Dec 2023 | 2.20M | -2.08M | -94.6% |
| Mar 2024 | 5.88M | 825K | 14.02% |
| 2027 | 27.52M | 2.11M | 7.7% |
|---|
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | 13.47% |
| 2022 | |
| 2023 |
| Jun 2023 | 31393000 | 7.94M | 25.31% |
|---|---|---|---|
| Sep 2023 | 36770000 | 16.88M | 45.93% |
| Dec 2023 | 33958000 | 15.96M | 47.01% |
| Mar 2024 | 30391000 | 11.37M | 37.42% |
| Jun 2023 | -4.90M | -58K | 0 |
|---|---|---|---|
| Sep 2023 | -4.14M | -313K | 0 |
| Dec 2023 | -2.01M | -305K | -364.97M |
| Mar 2024 | -2.71M | -154K | 0 |
Pulmatrix alternative data
| Aug 2023 | 28 |
|---|---|
| Sep 2023 | 28 |
| Oct 2023 | 28 |
| Nov 2023 | 28 |
| Dec 2023 | 28 |
| Jan 2024 | 28 |
| Feb 2024 | 28 |
| Mar 2024 | 28 |
| Apr 2024 | 28 |
| May 2024 | 22 |
| Jun 2024 | 22 |
| Jul 2024 | 22 |
Pulmatrix other data
| Period | Buy | Sel |
|---|---|---|
| Apr 2018 | 7227000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | MCGUIRE TERRANCE director | Series A Warrant (right to buy) | 1,150,000 | N/A | N/A | ||
Purchase | MCGUIRE TERRANCE director | Common Stock | 1,150,000 | N/A | N/A | ||
Purchase | GILLIS STEVEN director | Series A Warrant (right to buy) | 1,150,000 | N/A | N/A | ||
Purchase | GILLIS STEVEN director | Common Stock | 1,150,000 | N/A | N/A | ||
Purchase | SHERMAN MATTHEW L director | Common Stock | 20,000 | N/A | N/A | ||
Purchase | IWICKI MARK T director | Common Stock | 307,000 | N/A | N/A | ||
Purchase | IWICKI MARK T director | Common Stock | 307,000 | N/A | N/A | ||
Purchase | MCGUIRE TERRANCE director | Series A Warrant (right to buy) | 1,150,000 | N/A | N/A | ||
Purchase | MCGUIRE TERRANCE director | Common Stock | 1,150,000 | $0.11 | $124,200 | ||
Option | HAVA DAVID L. officer: Chief Scientific Officer | Stock Option (Right to Buy) | 2,263 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q2 2015 14 Nov 2014 | Q2 2015 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Teofilo David Raad MBA (1970) Pres, Chief Executive Officer & Director | $702,970 |
| Ms. Michelle S. Siegert (1961) Vice President of Fin. and Principal Financial & Accounting Officer | $390,340 |
-
What's the price of Pulmatrix stock today?
One share of Pulmatrix stock can currently be purchased for approximately $4.64.
-
When is Pulmatrix's next earnings date?
Unfortunately, Pulmatrix's (PULM) next earnings date is currently unknown.
-
Does Pulmatrix pay dividends?
No, Pulmatrix does not pay dividends.
-
How much money does Pulmatrix make?
Pulmatrix has a market capitalization of 21.03M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 20.21% to 7.3M US dollars.
-
What is Pulmatrix's stock symbol?
Pulmatrix, Inc. is traded on the NASDAQ under the ticker symbol "PULM".
-
What is Pulmatrix's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Pulmatrix?
Shares of Pulmatrix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Pulmatrix's key executives?
Pulmatrix's management team includes the following people:
- Mr. Teofilo David Raad MBA Pres, Chief Executive Officer & Director(age: 55, pay: $702,970)
- Ms. Michelle S. Siegert Vice President of Fin. and Principal Financial & Accounting Officer(age: 64, pay: $390,340)
-
How many employees does Pulmatrix have?
As Jul 2024, Pulmatrix employs 22 workers, which is 21% less then previous quarter.
-
When Pulmatrix went public?
Pulmatrix, Inc. is publicly traded company for more then 11 years since IPO on 21 Mar 2014.
-
What is Pulmatrix's official website?
The official website for Pulmatrix is pulmatrix.com.
-
Where are Pulmatrix's headquarters?
Pulmatrix is headquartered at 99 Hayden Avenue, Lexington, MA.
-
How can i contact Pulmatrix?
Pulmatrix's mailing address is 99 Hayden Avenue, Lexington, MA and company can be reached via phone at +7 813572333.
Pulmatrix company profile:
Pulmatrix, Inc.
pulmatrix.comNASDAQ
22
Biotechnology
Healthcare
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Lexington, MA 02421
CIK: 0001574235
ISIN: US74584P3010
CUSIP: 74584P301
